Schedule 13G Amendment No.4

-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, IZAHr2WwHehCOAlFeB4t7LgB8UxJC04nr9KAeTxVoIWC077hL6IclNsHL+/hqDIf wUpogAYpxXxzFQe/CNQUlQ== 0001193125-06-031863.txt : 20060215 0001193125-06-031863.hdr.sgml : 20060215 20060214210003 ACCESSION NUMBER: 0001193125-06-031863 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20060215 DATE AS OF CHANGE: 20060214 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: KOSAN BIOSCIENCES INC CENTRAL INDEX KEY: 0001110206 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 943217016 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-60269 FILM NUMBER: 06619440 BUSINESS ADDRESS: STREET 1: 3832 BAY CENTER PLACE CITY: HAYWARD STATE: CA ZIP: 94545 BUSINESS PHONE: 5107328400 MAIL ADDRESS: STREET 1: 3832 BAY CENTER PLACE CITY: HAYWARD STATE: CA ZIP: 94545 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: SANTI DANIEL V MD PHD CENTRAL INDEX KEY: 0001135141 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: BUSINESS PHONE: 5107328400 MAIL ADDRESS: STREET 1: 3832 BAY CENTER PLACE CITY: HAYWARD STATE: CA ZIP: 94545 SC 13G/A 1 dsc13ga.htm SCHEDULE 13G AMENDMENT NO.4 Schedule 13G Amendment No.4

SEC 1745

(02-02)

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.


OMB APPROVAL
OMB Number:		3235-0145
Expires:		December 31, 2005
Estimated average burden
hours per response . . . . . . . . . . . . . . . . . .11

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 4)*

Kosan Biosciences Incorporated

(Name of Issuer)

Common Stock

(Title of Class of Securities)

50064W 107

(CUSIP Number)

December 31, 2005

(Date of Event Which Requires Filing of This Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

¨ Rule 13d-1(b)

¨ Rule 13d-1(c)

x Rule 13d-1(d)

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Page 1 of 5

CUSIP No. 50064W 107


1.		Name of Reporting Persons I.R.S. Identification No(s). of above person(s) (entities only) Daniel V. Santi, M.D., Ph.D.
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) (b)
3.		SEC USE ONLY
4.		Citizenship or Place of Organization United States

Number of

Beneficially

Owned by

Each

Reporting

Person

With:

5. Sole Voting Power

4,088,920*

6. Shared Voting Power

66,500

7. Sole Dispositive Power

4,088,920*

8. Shared Dispositive Power

66,500


9.		Aggregate Amount Beneficially Owned by Each Reporting Person 4,155,420*
10.		Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
11.		Percent of Class Represented by Amount in Row (9) 14.0%
12.		Type of Reporting Person (See Instructions) IN

*	Includes 415,778 shares that the Reporting Person has the right to acquire pursuant to options exercisable within 60 days after December 31, 2005.

Page 2 of 5

Item 1.

(a)

Name of Issuer

Kosan Biosciences Incorporated

Address of Issuer’s Principal Executive Offices

3832 Bay Center Place

Hayward, CA 94545

Item 2.

(a)

Name of Person Filing

Daniel V. Santi, M.D., Ph.D.

(b)

Address of Principal Business Office or, if none, Residence

c/o Kosan Biosciences Incorporated

3832 Bay Center Place

Hayward, CA 94545

(c)

Citizenship

United States

(d)

Title of Class of Securities

Common Stock

(e)

CUSIP Number

50064W 107

Item 3.

Not applicable

Page 3 of 5



Item 4.	Ownership

	Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

	(a)	Amount Beneficially Owned:

		4,155,420, which includes 415,778 shares that the Reporting Person has the right to acquire pursuant to options exercisable within 60 days after December 31, 2005

	(b)	Percent of Class:

		14.0%

	(c)	Number of shares as to which the person has:

		(i)	Sole power to vote or to direct the vote: 4,088,920, which includes 415,778 shares that the Reporting Person has the right to acquire pursuant to options exercisable within 60 days after December 31, 2005

		(ii)	Shared power to vote or to direct the vote: 66,500

		(iii)	Sole power to dispose or to direct the disposition of 4,088,920, which includes 415,778 shares that the Reporting Person has the right to acquire pursuant to options exercisable within 60 days after December 31, 2005

		(iv)	Shared power to dispose or to direct the disposition of 66,500

Item 5.	Ownership of Five Percent or Less of a Class

	Not applicable

Item 6.	Ownership of More than Five Percent on Behalf of Another Person

	Not applicable

Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

	Not applicable

Item 8.	Identification and Classification of Members of the Group

	Not applicable

Item 9.	Notice of Dissolution of a Group

	Not applicable

Item 10.	Certification

	Not applicable

Page 4 of 5

[SIGNATURE]

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 14, 2006

Date

/s/ Daniel V. Santi

Signature

Daniel V. Santi, M.D., Ph.D. Chairman & CEO

Name/Title

Page 5 of 5

-----END PRIVACY-ENHANCED MESSAGE-----